UK markets closed

Arrowhead Pharmaceuticals, Inc. (0HI3.L)

LSE - LSE Delayed price. Currency in USD
Add to watchlist
22.03-0.22 (-0.99%)
At close: 04:49PM BST
Currency in USD

Valuation measures4

Market cap (intra-day) N/A
Enterprise value N/A
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)N/A
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.72
52-week change 315.52%
S&P500 52-week change 322.36%
52-week high 341.86
52-week low 320.75
50-day moving average 332.83
200-day moving average 331.06

Share statistics

Avg vol (3-month) 31.78k
Avg vol (10-day) 31.82k
Shares outstanding 588.02M
Implied shares outstanding 6N/A
Float 8118.95M
% held by insiders 14.49%
% held by institutions 167.25%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 4N/A
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Sept 2023
Most-recent quarter (mrq)31 Dec 2023

Profitability

Profit margin -163.32%
Operating margin (ttm)-3,845.25%

Management effectiveness

Return on assets (ttm)-24.66%
Return on equity (ttm)-106.24%

Income statement

Revenue (ttm)181.74M
Revenue per share (ttm)1.70
Quarterly revenue growth (yoy)-94.30%
Gross profit (ttm)N/A
EBITDA -285.35M
Net income avi to common (ttm)-296.81M
Diluted EPS (ttm)-1.08
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)213.38M
Total cash per share (mrq)1.72
Total debt (mrq)392.27M
Total debt/equity (mrq)225.81%
Current ratio (mrq)3.73
Book value per share (mrq)1.49

Cash flow statement

Operating cash flow (ttm)-196.21M
Levered free cash flow (ttm)-317.24M